The incidence of mutations in patients who had achieved very low BCR-ABL levels at any time during imatinib therapy
Consecutive BCR-ABL values in 214 patients . | No. patients (%) . | No. patients (%) . | Mutation analysis (%) . |
|---|---|---|---|
| Rise of more than 2-fold | 56 of 214 (26) | ||
| Lowest BCR-ABL/BCR% value achieved less than 0.1 | 9 of 56 (16) | Mutations, 3 of 9 (33) | |
| Lowest BCR-ABL/BCR% value achieved 0.1 or greater | 47 of 56 (84) | Mutations, 31 of 47 (66) | |
| Stable or decreasing levels | 158 of 214 (74) | ||
| Lowest BCR-ABL/BCR% value achieved less than 0.1 | 70 of 158 (44) | Mutations, 0 of 70 (0) | |
| Lowest BCR-ABL/BCR% value achieved 0.1 or greater | 88 of 158 (56) | Mutations, 1 of 88 (1.1) |
Consecutive BCR-ABL values in 214 patients . | No. patients (%) . | No. patients (%) . | Mutation analysis (%) . |
|---|---|---|---|
| Rise of more than 2-fold | 56 of 214 (26) | ||
| Lowest BCR-ABL/BCR% value achieved less than 0.1 | 9 of 56 (16) | Mutations, 3 of 9 (33) | |
| Lowest BCR-ABL/BCR% value achieved 0.1 or greater | 47 of 56 (84) | Mutations, 31 of 47 (66) | |
| Stable or decreasing levels | 158 of 214 (74) | ||
| Lowest BCR-ABL/BCR% value achieved less than 0.1 | 70 of 158 (44) | Mutations, 0 of 70 (0) | |
| Lowest BCR-ABL/BCR% value achieved 0.1 or greater | 88 of 158 (56) | Mutations, 1 of 88 (1.1) |